(Q36547758)

14 August 2017

1 reference

title

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors (English)

1 reference

14 August 2017

1 reference

D A Haber

1

1 reference

14 August 2017

D W Bell

2

1 reference

14 August 2017

R Sordella

3

1 reference

14 August 2017

E L Kwak

4

1 reference

14 August 2017

N Godin-Heymann

5

1 reference

14 August 2017

S V Sharma

6

1 reference

14 August 2017

T J Lynch

7

1 reference

14 August 2017

J Settleman

8

1 reference

14 August 2017

publication date

1 January 2005

1 reference

Cold Spring Harbor Symposia on Quantitative Biology

14 August 2017

published in

1 reference

14 August 2017

volume

70

1 reference

14 August 2017

page(s)

419-426

1 reference

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Pulmonary adenocarcinomas with mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1101%2FSQB.2005.70.043

21 January 2018

Identifiers

DOI

10.1101/SQB.2005.70.043

1 reference

14 August 2017

1 reference